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Abstract 
As of September 30, 2015, a total of 1589 laboratory‑confirmed cases of infection with the Middle East respiratory 
syndrome coronavirus (MERS‑CoV) have been reported to the World Health Organization (WHO). At present there is 
no effective specific therapy against MERS‑CoV. The use of convalescent plasma (CP) has been suggested as a potential 
therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as 
its safety and clinical and laboratory effects in critically ill patients with MERS‑CoV infection. We will also examine the 
pharmacokinetics of the MERS‑CoV antibody response and viral load over the course of MERS‑CoV infection. This study 
will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MERS‑CoV infection. In the 
CP collection phase, potential donors will be tested by the enzyme linked immunosorbent assay (ELISA) and the indirect 
fluorescent antibody (IFA) techniques for the presence of anti‑MERS‑CoV antibodies. Subjects with anti‑MERS‑CoV IFA 
titer of ≥1:160 and no clinical or laboratory evidence of MERS‑CoV infection will be screened for eligibility for plasma 
donation according to standard donation criteria. In the CP therapy phase, 20 consecutive critically ill patients admitted 
to intensive care unit with laboratory‑confirmed MERS‑CoV infection will be enrolled and each will receive 2 units of 
CP. Post enrollment, patients will be followed for clinical and laboratory outcomes that include anti‑MERS‑CoV antibod‑
ies and viral load. This protocol was developed collaboratively by King Abdullah International Medical Research Center 
(KAIMRC), Gulf Cooperation Council (GCC) Infection Control Center Group and the World Health Organization—Inter‑
national Severe Acute Respiratory and Emerging Infection Consortium (ISARIC‑WHO) MERS‑CoV Working Group. It was 
approved in June 2014 by the Ministry of the National Guard Health Affairs Institutional Review Board (IRB). A data safety 
monitoring board (DSMB) was formulated. The study is registered at http://www.clinicaltrials.gov (NCT02190799).
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Background
The Middle East respiratory syndrome coronavirus 
(MERS-CoV) was initially identified in September 2012 
from samples obtained from a Saudi Arabian patient who 
developed severe acute respiratory infection and sub-
sequent acute renal failure leading to death (Zaki et  al. 
2012). As of September 30, 2015, a total of 1589 cases 
have been identified with 567 related deaths (World 
Health Orgnization 2015). To date, there is no specific 
treatment of proven effect for MERS-CoV infection. 
Public Health England and the International Severe 
Acute Respiratory and Emerging Infection Consor-
tium (ISARIC) have published a decision support tool 
for clinicians managing cases of MERS-CoV infection. 
The document suggests that current evidence is strong-
est for testing convalescent plasma (CP) or other thera-
peutics which contain neutralizing antibodies (such as 
hyperimmune immunoglobulin) for treatment of serious 
MERS-CoV illness (Public Health England 2015). Prior 
experience in SARS and severe influenza suggest that 
CP may be considered for patients who are deteriorat-
ing (despite other specific and supportive therapy) and 
in whom the virus remains detectable (Hung et al. 2011; 
Luke et al. 2006; Cheng et al. 2005; Kong and Zhou 2006; 
Yeh et al. 2005). A recent systematic review of 32 reports 
from SARS and severe influenza concluded that CP ther-
apy appears safe and may reduce mortality, especially 
if administered early in the illness (Mair-Jenkins et  al. 
2015). An exploratory post hoc meta-analysis showed 
a statistically significant reduction in the pooled odds 
of mortality following treatment compared to placebo 
or no therapy (odds ratio 0.25; 95 % confidence interval 
0.14–0.45; I2  =  0  %) (Mair-Jenkins et  al. 2015). Citing 
case series, the authors commented that (1) patients with 
severe presentations appeared to demonstrate temporal 
clinical improvements after treatment with CP and (2) 
administration as early as possible in the diseases course 
appears to be associated with greatest potential clinical 
effect. One randomized clinical trial (RCT) in critically ill 
influenza A (H1N1pdm09)-infected patients found a sur-
vival benefit when hyperimmune globulin was adminis-
tered within 5 days of symptom onset (Hung et al. 2013).
However, there are no data at present to support the 
efficacy of CP treatment in MERS-CoV infection; there-
fore, it has been recommended to administer CP only 
in the context of a clinical trial. While an RCT will be 
required to evaluate effectiveness, evaluating effective-
ness on clinical endpoints such as mortality will likely 
require several hundred to several thousand seriously ill 
MERS-CoV patients in order to achieve sufficient sta-
tistical power, anticipating reasonable potential effect 
sizes. Additionally, CP from different MERS-CoV sur-
vivors will likely contain differing levels of neutralizing 
anti-MERS-CoV antibodies. Since seriously ill MERS-
CoV-infected patients may have detectable viral RNA 
in various locations that can be sampled (for example 
lower respiratory tract secretions) for prolonged periods, 
it might be possible to first determine the relationship 
between neutralizing antibody dose and antiviral effects 
on clinical and laboratory features in a small open-label 
study. This information would be very helpful to design 
of an RCT and in determining the most appropriate neu-
tralizing antibody dose, or dosing range for the study. 
This may also inform dose selection for follow-on anti-
MERS-CoV antibody preparations currently in pre-
clinical development (for example, neutralizing human 
monoclonal antibodies, polyclonal human neutralizing 
immunoglobulin derived from transchromosomic cattle 
(personal communication, Thomas C. Luke).
Therefore, we plan to conduct a 2-phase study. In the 
first phase (CP collection phase), we will explore the fea-
sibility of collection of CP from donors who have signifi-
cant titers of anti-MERS-CoV antibodies. In the second 
phase, patients with MERS-CoV infection will be treated 
with CP. If the protocol is feasible, safe, and associated 
with temporal changes in viral load and illness, this pilot 
study will inform a larger concealed intervention, pla-
cebo-controlled RCT that is powered to evaluate efficacy 




The inclusion criteria for screening potential CP donors 
include individuals from the following cohorts: (1) 
healthcare workers (HCWs) who had documented expo-
sure to MERS-CoV, (2) recovering patients from con-
firmed or suspected MERS-CoV infection, (3) household 
contacts of known MERS-CoV infected patients and (4) 
other subjects who are willing to donate plasma. Females 
with prior pregnancy will not be included for donation.
CP therapy phase
We will screen consecutive critically ill patients admitted 
to the intensive care unit or other areas of the hospital 
where critically ill patients receive care for the following 
criteria:
Inclusion criteria
1. Critical illness as defined by one or more of the fol-
lowing: admission to an ICU; current receipt of 
mechanical invasive or non-invasive ventilation; par-
tial pressure of oxygen to fraction of inspired oxygen 
ratio (PaO2:FiO2) of  <300  mmHg; current receipt 
of intravenous vasoactive medications to maintain 
mean arterial pressure >65 mmHg; new-onset (since 
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development of MERS-CoV symptoms) receipt of 
renal replacement therapy or extra-corporeal life 
support.
2. Laboratory-confirmed MERS-CoV infection (by real-
time reverse-transcription polymerase chain reaction 
rRT-PCR).
3. Age of more than or equal to 14 years.
Exclusion criteria
1. Symptomatic illness exceeding two weeks (14  days) 
at time of enrollment.
2. Negative rRT-PCR from respiratory secretions or 
blood within 48 h prior to assessment of eligibility.
3. History of allergic reaction to blood or plasma prod-
ucts (as judged by the investigator).
4. Known IgA deficiency.
5. Medical conditions in which receipt of 500 mL intra-
vascular volume may be detrimental to the patient 
(e.g., actively decompensated congestive heart fail-
ure).
Informed consent
The research coordinator and/or physician investigator 
will explain the objectives of this study and its potential 
risks and benefits to the donor or patient (or to his/her 
surrogate decision maker) and will obtain the following 
consent forms in and as appropriate:
CP collection phase
1. Consent for MERS-CoV serologic testing and MERS-
CoV RT-PCR for donors.
2. Consent for CP donation for those who have elevated 
anti-MERS-CoV titers as described below.
CP therapy phase
1. Consent for enrollment in the CP therapy phase.
2. Consent for enrollment in the observational study 
where NO intervention will be received, but partici-
pants will still have blood (and possibly respiratory) 
samples taken—for participants not receiving the 
intervention.
Study procedures
For the CP collection phase
1. Eligible candidates for CP donation (as per the inclu-
sion and exclusion criteria above) will be approached 
to have their blood tested for anti-MERS-CoV serol-
ogy (see laboratory methods). Subjects who are sero-
positive will be screened subsequently for MERS-
CoV rRT-PCR to exclude active infection.
2. Subjects with anti-MERS-CoV-specific titer  ≥1:160 
and no clinical (not requiring medical support for 
respiratory or other organ function) or laboratory 
(rRT-PCR negative) evidence of MERS-CoV infec-
tion will be screened for eligibility for plasma dona-
tion according to the standard criteria in accordance 
with the WHO Guidelines Assessing Donor Suitabil-
ity for Blood Donation (The World Health Organiza-
tion 2015).
3. Those who meet the plasma donation criteria will be 
invited for donation according to the WHO Blood Regu-
lators Network (BRN) Position Paper on Collection and 
use of convalescent plasma or serum as an element in 
Middle East respiratory syndrome coronavirus response 
(WHO Blood Regulators Network (BRN) 2015). Plasma 
may be collected by apheresis as frequently as twice 
every month, as appropriate for the individual donor. 
Collection will be performed by trained blood bank staff 
operating under the standard operating procedures in 
certified facilities. The collected frozen plasma will be 
stored in the blood bank after being tested for serology 
of hepatitis B and C viruses (HBV and HCV), human 
immunodeficiency virus (HIV), malaria, syphilis and 
human T-lymphotropic virus (HTLV) types I and II 
and nucleic acid testing (NAT) for HBV, HCV and HIV 
according to international guidelines.
For the CP therapy phase
1. Critically ill MERS-CoV patients who meet the above 
patient eligibility criteria will be approached for con-
sent.
2. Patients will have their blood type determined. CP 
must be ABO compatible with the recipient’s blood 
type.
3. The trial intervention include the administration of 2 
units of CP. Each unit of plasma will be given over 
2  h with an interval of 1  h between the two units. 
Plasma transfusion will be done in accordance with 
the standard policies for administration of blood 
products.
Co‑interventions
The clinical team will have full, independent control of 
patient management and as such, management other 
than CP therapy will not be influenced by the interven-
tion or study team. Co-interventions, including corti-
costeroids, ribavirin, intravenous immunoglobulin and 
interferon, will be documented on the study case report 
forms.
Co‑enrollment
Co-enrollment in another study is permissible as long 
as the enrollment in the other study would not be at 
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moderate to high risk of biologically or analytically 
confounding the results of this study, as judged by the 
study management committee and as per the published 
guidelines.
Frequency and duration of follow‑up
Clinical and laboratory data will be collected at baseline, 
30  min after first dose, 30  min after second dose, study 
days 1, 3, 5, 7, 14, and 28.
Outcome measures
CP collection phase
We will explore the feasibility of the study interven-
tion, as measured by ability to screen potential plasma 
donors, and derive sufficient plasma to enrol 20 patients 
in a 12 months period. We will also qualitatively describe 
logistical challenges experienced through the conduct of 
this study, including ethical, administrative and regula-
tory challenges.
CP therapy phase
1. We will establish safety of the study intervention, 
as measured by number of serious adverse events 
related to study intervention (adverse events include 
development of complications of intravascular vol-
ume overload and clinical pulmonary edema by tem-
porally related-shortness of breath, chest radiograph 
findings and change in oxygenation requirements; 
development of transfusion-related acute lung injury 
(TRALI) or substantial allergy or anaphylaxis). These 
serious events will be adjudicated by a committee of 
3 investigators.
2. Clinical Outcomes We will measure (1) sequential 
organ failure assessment (SOFA) scores on study days 
1, 3, 5, 7, 14, and 28 (2) requirement for organ sup-
port (oxygen and ventilation; dialysis; vasopressors) 
after enrollment; (3) length of stay in ICU defined as 
the number of calendar days between admission and 
final discharge from ICU for the same ICU admission 
of enrollment; and duration of mechanical ventila-
tion, defined as the number of calendar days between 
start and final liberation from mechanical ventilation 
for the same ICU admission of enrollment and hospi-
tal length of stay as defined as the number of calen-
dar days between admission to hospital and final dis-
charge from hospital for the same hospital admission; 
and (4) vital outcome (mortality) in ICU, hospital and 
at 28 days.
3. Other clinical outcomes include “ICU-free days”, 
defined as the number of days that patients are not 
in ICU in the first 28 days after enrollment. Patients 
who die within 28  days will be counted separately, 
and not categorised by ICU-free days. Similarly, “ven-
tilator-free days” is defined as the number of days 
that patients do not receive mechanical ventilation 
in the first 28 days after enrollment. “Renal replace-
ment therapy-free days” and “vasopressor-free days” 
are defined in a similar way. Serial chest radiograph 
findings, as obtained by the clinical team will also be 
recording as per case report form, graded as unilat-
eral or bilateral infiltrates, in 1–4 quadrants.
4. Laboratory Outcomes We will measure the following 
laboratory outcomes:
(a) The serum level of anti-MERS-CoV antibodies 
before and after administration of CP.
(b) MERS-CoV viral load (the primary laboratory 
outcome is viral clearance from all sampled sites 
by day 3 after administration of CP).
Laboratory procedures
1. Measuring anti-MERS-CoV antibodies level in 
donor and participant serum
 MERS-CoV antibodies will be tested first by the 
enzyme linked immunosorbent assay (ELISA) as a 
screening test (Drosten et al. 2014; Müller et al. 2015) 
according to manufacturer’s instructions (Euroim-
mun AG, Lübeck, Germany). Results will be reported 
as the optic density (OD) ratio, which is calculated as 
the OD value of the patient’s sample divided by the 
calibrator OD value. We will use the cut-off values 
recommended by the manufacturer: a ratio of <0.8 is 
considered negative, >0.8 and <1.1 borderline and a 
ratio of >1.1 is considered positive.
 Confirmation will be done by the Indirect Fluores-
cent Antibody (IFA, Euroimmun AG, Lübeck, Ger-
many) according to manufacturer’s instructions. 
Samples with  ≥1:10 will be considered reactive 
according to the manufacturer’s instructions, sub-
jects will be considered candidate for plasma dona-
tion if they have titers of ≥1:160; which is a similar 
threshold to what has been used in a convalescent 
plasma trial for H1N1 influenza (Hung et al. 2011).
Administrative and ethical aspects
The primary coordinating study center is the Intensive 
Care Department at King Saud bin Abdulaziz University 
for Health Sciences (KSAUHS) in Riyadh, Saudi Ara-
bia. The study will be conducted in accordance with the 
ethical principles of the Declaration of Helsinki and the 
International Conference on Harmonization-Good Clini-
cal Practice (ICH-GCP) guidelines.
Several measures will be taken to ensure optimal com-
pliance with the study protocols. Before launching the 
study, ICU physicians and nurses will attend the train-
ing sessions with special emphasis on any adverse events 
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noted during the intervention. The Steering Committee, 
led by the principal investigator, will be responsible for 
overseeing the conduct of the trial, for upholding or mod-
ifying study procedures as needed, addressing challenges 
with protocol implementation, formulating the analysis 
plan, reviewing and interpreting the data and preparing 
the manuscript. The study also has an independent data 
safety monitoring board (DSMB) which is responsible 
for reviewing reports submitted to the regarding safety 
of study patients, protocol adherence and may making 
recommendations to continue or terminate the study 
based on safety analysis results. The DSMB, composed 
of 5 members (who are named at the end of this docu-
ment) will meet at the beginning of phase II of the study 
followed by 6-monthly or as needed.
Safety measures
In the event of an acute transfusion reaction, the transfu-
sion will be stopped immediately and must be reported 
to the blood bank the principal investigator immediately 
as well as to the study management committee. All the 
serious adverse events (SAE) adjudicated as related to the 
study intervention will be reported to the Institutional 
Research Ethics Board and the DSMB.
Statistical and analytical plan
Sample size calculation
This is an exploratory study, aimed at rectifying the cur-
rent lack of information on the use of CP to treat MERS-
CoV infection. Due to the exploratory nature of this study 
and the paucity of sequential data on viral RNA levels in 
respiratory tract and blood samples from MERS-CoV-
infected patients, and on their clinical progress, the sam-
ple size is fixed at 20, which is a realistic target for a study 
of 12 months duration. The sample size of 20 is sufficient 
to reach a conclusion that the 28-day survival rate signif-
icantly exceeds 60  % (p =  0.032, 2-sided) if 17 or more 
patients survive for the 28 days of follow-up. This would 
represent promising evidence to motivate a full-scale 
comparative clinical trial.
Statistical analyses
Analysis of viral load data
1. Serial MERS-CoV viral load measurements will be 
displayed as box and whisker plots for the 20 treated 
patients against time.
2. The probability of a patient having an undetectable 
viral load from all sampled sites by day 3 after admin-
istration of therapy will be estimated by the propor-
tion of the 20 treated patients for whom this occurs. 
An exact, conservative, two-sided confidence inter-
val for this probability will be calculated using the 
method of Clopper and Pearson (1934).
3. The relationship between log viral load at day 3 and 
the neutralizing antibody dose received will be char-
acterised by fitting a regression model to the data 
from the 20 treated patients. The log viral load at 
baseline will be included in this model.
4. The relationship between the probability of a 
patient having an undetectable viral load by day 3 
and the neutralizing antibody dose received will 
be characterised by fitting a log-logistic regression 
model to the data from the 20 treated patients. The 
log viral load at baseline will be included in this 
model.
Analysis of clinical data
1. The SOFA score and indicators of whether the 
patient requires organ support via oxygen and venti-
lation, dialysis or vasopressors will be plotted against 
time.
2. The relationships between the SOFA score at day 3 
and the neutralizing antibody dose received, and 
between receipt of any type of organ support during 
the 28 days of observation and the neutralizing anti-
body dose received, will be characterised by fitting 
a logistic regression model to the data from the 20 
treated patients. The log viral load at baseline will be 
included in these models.
3. The vital status (alive or dead) of each patient will be 
recorded for all days 0–28. The proportion alive will 
be plotted against time.
4. The relationship between the hazard of death and the 
neutralizing antibody dose received will be charac-
terised by fitting a Cox proportional hazards regres-
sion model to the data from the 20 treated patients. 
The log viral load at baseline will be included in this 
model.
5. The probability of a patient dying on or before 
28  days will be estimated by the proportion of the 
20 treated patients for whom this occurs. An exact, 
conservative, two-sided confidence interval for this 
probability will be calculated using the method of 
Clopper and Pearson (1934).
6. The time from infection/exposure and sample collection 
in days, duration from infection/exposure to CP therapy, 
length of stay in ICU; the number of ICU-free days; 
the duration of mechanical ventilation; the numbers of 
ventilator-free days, of renal replacement therapy-free 
days, and of vasopressor-free days; and the length of stay 
in hospital will be presented as histograms, and suitable 
summary statistics will be computed.
Stratified analyses
We will conduct exploratory stratified analyes based on 
(1) the time between symptom onset and CP therapy 
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initiation, (2) comorbidities, (3) co-intervention; and (4) 
baseline severity (SOFA scores) at treatment initiation.
The SAS System for Windows version 9.3 (SAS Insti-
tute, Inc., Cary, North Carolina) and R will be used for all 
analyses.
Discussion and current status
This protocol was developed collaboratively by King 
Abdullah International Medical Research Center 
(KAIMRC), Gulf Cooperation Council (GCC) Infection 
Control Center Group and the World Health Organi-
zation—International Severe Acute Respiratory and 
Emerging Infection Consortium (ISARIC-WHO) MERS-
CoV Working Group. It was approved by the Ministry of 
the National Guard Health Affairs Institutional Review 
Board (IRB) (approval number IRBC/13/244, 5th June 
18, 2014) and has been registered at clinicaltrials.gov 
(NCT02190799).
If proven effective, CP therapy is an attractive thera-
peutic option for MERS-CoV infection. Besides the bio-
logic plausibility of this therapy, it is easy to obtain and 
administer, relatively inexpensive, and is likely to be 
acceptable to patients and treating teams. Side effects are 
unlikely to differ from those of transfusion of any other 
fresh frozen plasma. We believe this study protocol sets 
the stage to a large efficacy trial.
The strengths and weaknesses of the study protocol 
should be noted. In the CP collection phase subjects will 
be enrolled from 4 different cohorts, in order to explore all 
potential donors. It is unknown, at this point, which sub-
jects are likely to have high antibody titers and therefore 
be CP donors. We are hoping that this feasibility study will 
help identifying a group of superdonors who have very high 
titers. By identifying the characteristics of such individuals, 
a more focused approach for donation can be followed. The 
CP therapy phase is not designed to establish efficacy; such 
objective requires an adequately powered randomized con-
trolled trial. However, we believe performing this feasibility 
study is an essential step to examine the safety, clinical and 
laboratory effects and the pharmacokinetics of the MERS-
CoV antibody response. The study involves giving critically 
ill patients this therapy in a controlled monitored setting. 
However, a recent systematic review suggested that early 
treatment with CP is likely to be more effective than late 
treatment (Mair-Jenkins et al. 2015). Therefore, if the feasi-
bility study shows that CP is safe and feasible, the next step 
should be a randomized controlled trial that is sufficiently 
powered to detect effect on mortality and enrolls patients 
early in the course of the disease.
Conclusions
Our study is anticipated to provide information about 
the feasibility of collecting convalescent plasma in large 
quantities for therapeutic use in a large numbers of 
MERS-CoV patients. The data is anticipated to inform 
about the relation between the antibody titers in the CP 
and viral clearance and other laboratory and clinical end-
points. This data will be critical in planning a larger RCT 
to examine the efficacy of CP on patients with MERS-
CoV infection.
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